**Lay Description of Important Outcomes**

With the support of METAvivor, we have made great progress on our research to advance a novel treatment paradigm for patients with liver dominant metastatic breast cancer. We have optimized our immune profile panel that will allow us to analyze the changes that take place when patients are treated with a combination of immunotherapy and Yttrium-90 radioembolization. We are also in the final stages of preparing the protocol for our clinical trial of this novel therapy and anticipate enrolling our first patients in the near future. This study has the potential to improve outcomes for individuals battling this aggressive cancer and make a profound impact on patients and families affected by this disease.